These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35086504)

  • 1. An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.
    Mbwambo J; Kaaya S; Lema I; Burant CJ; Magwiza C; Madundo K; Njiro G; Blixen CE; Cassidy KA; Levin JB; Sajatovic M
    BMC Psychiatry; 2022 Jan; 22(1):62. PubMed ID: 35086504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.
    Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD
    J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Injectable Antipsychotic Medication Plus Customized Adherence Enhancement in Poor Adherence Patients With Bipolar Disorder.
    Sajatovic M; Levin JB; Ramirez LF; Cassidy KA; McNamara N; Fuentes-Casiano E; Wilson B; Appling D; S FB
    Prim Care Companion CNS Disord; 2021 Sep; 23(5):. PubMed ID: 34534421
    [No Abstract]   [Full Text] [Related]  

  • 4. A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.
    Sajatovic M; Ramirez LF; Fuentes-Casiano E; Cage J; Tatsuoka C; Aebi ME; Bukach A; Cassidy KA; Levin JB
    J Clin Psychopharmacol; 2017 Dec; 37(6):702-707. PubMed ID: 28930768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A customized adherence enhancement program combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania: A pilot study methodological report.
    Mbwambo J; Kaaya S; Lema I; Blixen C; Cassidy KA; Levin JB; Sajatovic M
    Heliyon; 2019 Jun; 5(6):e01763. PubMed ID: 31198864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-Month, Prospective, Randomized Controlled Trial of Customized Adherence Enhancement Versus Bipolar-Specific Educational Control in Poorly Adherent Individuals With Bipolar Disorder.
    Sajatovic M; Tatsuoka C; Cassidy KA; Klein PJ; Fuentes-Casiano E; Cage J; Aebi ME; Ramirez LF; Blixen C; Perzynski AT; Bauer MS; Safren SA; Levin JB
    J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30256551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Medication Adherence Support Plus Long-Acting Injectable Antipsychotic Medication: A Post-Hoc Analysis of 3 Pilot Studies.
    Canales T; Rodman S; Conklin D; Sarna K; Sajatovic M; Levin JB
    Psychopharmacol Bull; 2022 Jun; 52(3):41-57. PubMed ID: 35815176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 11. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
    Maestri TJ; Mican LM; Rozea H; Barner JC
    Psychopharmacol Bull; 2018 Mar; 48(3):8-15. PubMed ID: 29713100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial.
    Priebe S; Bremner SA; Lauber C; Henderson C; Burns T
    Health Technol Assess; 2016 Sep; 20(70):1-122. PubMed ID: 27682868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia.
    Nakonezny PA; Lindow JC; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Byerly MJ
    Schizophr Res; 2020 Jun; 220():92-97. PubMed ID: 32269005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community perceptions of barriers to management of chronic psychotic disorders and knowledge and attitudes about long-acting injectable antipsychotic medication: qualitative study in Dar es Salaam, Tanzania.
    Blixen C; Lema I; Mbwambo J; Kaaya S; Levin JB; Sajatovic M
    BJPsych Open; 2020 Mar; 6(2):e27. PubMed ID: 32157988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa-McMillan A
    J Clin Psychiatry; 2012 Sep; 73(9):1224-33. PubMed ID: 22938760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
    Shymko G; Dobson L; Acacio MC; Grace T; Tadier S; Waters F
    Schizophr Res; 2023 Jan; 251():74-81. PubMed ID: 36587541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.
    Noordraven EL; Audier CH; Staring AB; Wierdsma AI; Blanken P; van der Hoorn BE; Roijen LH; Mulder CL
    BMC Psychiatry; 2014 Dec; 14():343. PubMed ID: 25438877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.
    Stroup TS; Bareis NA; Rosenheck RA; Swartz MS; McEvoy JP
    J Clin Psychiatry; 2018 Nov; 80(1):. PubMed ID: 30549494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 6-month, prospective, randomized controlled trial of customized adherence enhancement versus a bipolar-specific educational control in poorly adherent adolescents and young adults living with bipolar disorder.
    Levin JB; DelBello M; Modi AC; Briggs F; Forthun LF; McVoy M; Yala J; Cooley R; Black J; Conroy C; Sajatovic M
    Bipolar Disord; 2024 Nov; 26(7):696-707. PubMed ID: 39231780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.